Bayer HealthCare, a subgroup of Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the oral anticoagulant Xarelto, or rivaroxaban, used as a single drug intervention, was as effective and safe as the current dual drug approach of subcutaneous enoxaparin followed by Vitamin K antagonist, in treating patients with acute symptomatic pulmonary embolism and preventing them from developing a secondary venous blood clot.
Rivaroxaban showed similar overall bleeding rates, but was associated with significantly lower rates of major bleeding versus the current standard of care.
The company noted that Rivaroxaban was also proven effective in preventing recurrent venous blood clots in Phase III EINSTEIN-PE Study.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.